Today, the Army’s three multi-domain task forces — with two more in the works — may be the most tangible result of Harris’ charge.

BACKGROUND: Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism underlying cardiac benefits of exercise in DiaCM remains incompletely ...

A new research paper was published in Oncotarget , Volume 16, on May 8, 2025, titled "METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." In this study, researchers ...

A new research paper was published in Oncotarget, Volume 16, on May 8, 2025, titled "METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." ...

Figure 8: Schematic representation of METTL3-mediated OSCC progression via regulating the miR-146a-5p/SMAD4 axis. Overexpressed METTL3 (an oncogene) in OSCC cells enhances the processing of pri ...

DNA and RNA methylation, initially thought to operate as distinct pathways, have been shown to interact closely, shifting our understanding of gene regulation. A team of researchers from the ...

Silencing METTL3 in ECs abrogates the NLR family pyrin domain-containing 1 (NLRP1)-mediated inflammasome and monocyte adhesion induced by atheroprone flow, whereas METTL3 overexpression inhibits the ...

STC-15, an investigational RNA methyltransferase inhibitor, has shown promising clinical activity and an encouraging safety profile across various tumor types.

Blocking the METTL3 protein can increase sensitivity to chemotherapy in neuroblastoma, according to research from the University of Gothenburg. The study shows how specific RNA modifications ...

Moreover, METTL3 depletion/inhibition induces DNA damage and differentiation of MYCN overexpressing cells and increases vulnerability to chemotherapeutic drugs in MYCN -amplified patient-derived ...

Epics Therapeutics SA has described N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, infections, and ...